🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join me at #EAU2024 in sharing important information and resources around disease awareness for bladder cancer. Look forward to connecting with global partners this week! #urology #PFEcolleague

This year, in the U.S., more than 83,000 people will be diagnosed with bladder cancer, primarily non-muscle-invasive (NMIBC). We’re researching to advance #bladdercancer care options to help patients in need. #BladderCancerAwarenessMonth bit.ly/3y9Jqr3

A new opportunity to connect and collaborate is on the horizon! Excited to be part of #UROonco24 in Hungary today. Looking forward to insightful discussions and innovative ideas in the field of uro-oncology. Let's make a difference together! #PFEcolleague

Live from the UROonco conference! It's an inspiring day of learning in the field of URO oncology. #UROonco24 #PFEcolleague Great interactive meeting!

Excited to be part of the #IBCG24 retreat in Houston tomorrow. Honored to represent Pfizer’s commitment to advancing bladder cancer care through in-depth discussions and evaluation of existing data. Looking forward to meaningful conversations. #PFEcolleague

Day 1 of #IBCG24 is underway. Honored to contribute to discussions on advancing bladder cancer care and diving into existing data for better patient outcomes. Excited to share insights and collaborate with peers. #PFEcolleague #ibcg2024 IBCG

The countdown is on for #ESMO24 in Barcelona! Eager to engage in discussions on the future of cancer care and Pfizer's contributions to oncology advancements for bladder cancer patients. Let's collaborate for a brighter tomorrow! #PFEcolleague

🏃‍♂️🏃‍♂️🎯ready to start the ESMOrun5K ! Good friends here!! #ESMO2024 ESMO - Eur. Oncology Toni Choueiri, MD @GU Cast | Urology podcast! UroTarget Declan Murphy

Up for a 7am #OncoAlert run supporting patients with cancer together with friends and colleagues. Couldn’t be more proud of being within this community Now quick coffee and heading over to ESMO to collaborate with industry leaders on innovative oncology solutions #PFEcolleague

Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone. Full NIAGARA trial results: nej.md/4gmAqk3 #ESMO24

Breaking news (practice changing) from ESMO - Eur. Oncology #ESMO24 👉Tom Powles presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +|- durvalumab in MIBC #bladdercancer 👉Significant improvement in DFS (HR 0.68) & OS (HR 0.75) with durvalumab OncoAlert UroToday.com

This is a table to remember! Thorough comparisons across neoadjuvant trials in #bladdercancer from Elizabeth Plimack MD. #ESMO24 #ESMOAmbassadors ESMO - Eur. Oncology OncoAlert

The excitement is building as we approach #EMUC24! Looking forward to insightful discussions with multidisciplinary teams on innovative strategies to improve cancer care. Let’s drive progress together! #PFEcolleague

JUST IN: + pivotal trial for PD-1 in non-muscle invasive bladder cancer (NMIBC): The CREST trial of BCG +/- PD-1 sasanlimab in BCG-naïve, high-risk NMIBC met 1EP of EFS. This could signal a major shift in the bladder cancer field, and in "early stage" solid cancers in general.

Delighted to be part of this exciting collaboration. The landscape for NMIBC continues to evolve with improved disease control & preserved QOL . Thanks Félix Guerrero-Ramos Enrique Grande Bernadett Szabados Petros Grivas KSridhar Julia Brinkmann, MD MBA jim catto Faculty of Health | University of Sheffield Yüksel Ürün

On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC link.springer.com/article/10.100… Patients with high-risk non–muscle invasive bladder cancer (NMIBC) are typically treated with transurethral resection

There’s an unmet need for new therapies in high-risk non-muscle invasive #BladderCancer (NMIBC). See this article & video abstract for a global, multidisciplinary take on emerging therapies like PD-(L)1 inhibitors for pts with BCG-naive high-risk NMIBC: bit.ly/3EpR5VY

New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction + maintenance shows: •32% ⬇️of EFS event (HR 0.68, p=0.0095) •>50% reduction in HG recurrence •No difference in overall survival (OS interim HR 1.13, p=0.6791) #AUA25 #bladdercancer

Neal Shore joins us to discuss the CREST trial of sasanlimab +/- BCG in high-risk NMIBC from the Amer. Urol. Assn. 2025 Annual Meeting. Stacy Loeb, MD Alexander Kutikov MD Todd 〽️ Morgan, MD Maria J. Ribal Quoc-Dien Trinh, MD, MBA Angie Smith Dave Penson Ashish M. Kamat, MD, MBBS Sam S. Chang MD, MBA Peter Black spotifycreators-web.app.link/e/FM23xO73SSb

Here is a podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial which show and EFS advantage but with expected immune related toxicity. Here we discuss the highlights and risk benefit ratio. podcasts.apple.com/gb/podcast/the… #AUA25